Target Pipelines
In this product category, you will find reports in a tabular format providing you with the most uptodate competitive intelligence information about target-specific R&D pipelines. This low-cost product service provides information about active R&D projects for a given target in the format of Word tables.
Subscribe to
our newsletters!
Showing all 16 resultsSorted by latest
-
On demand upon order placementThis competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting Her3.€ 300.00
-
August of 2025This competitive intelligence report about DLL3-Targeted Therapy provides a competitor evaluation in the field of product candidates targeting delta-like ligand 3 (DLL3) as of August of 2025.€ 300.00
-
August of 2025This competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.€ 300.00
-
July of 2025This competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.€ 400.00
-
July of 2025This competitive intelligence report about Fibroblast Activation Protein (FAP) Targeted Therapy provides a competitor evaluation in the field of product candidates targeting Fibroblast Activation Protein (FAP) as of July of...€ 300.00
-
July of 2025This competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of...€ 200.00
-
July of 2025This competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as...€ 200.00
-
July of 2025This competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
April of 2024Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
-
July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.
-
July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
-
June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
-
May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00